Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16608604 | 0.90 | CHUK (0.37) | DGAT1CHUK | |
| SCHEMBL16608620 | 0.90 | CHUK (0.40) | DGAT1CHUK | |
| SCHEMBL20193151 | 0.87 | CHUK (0.34) | CHUKNFATC1GSK3BDYRK1AMAP3K5 | |
| SCHEMBL19114590 | 0.87 | CHUK (0.34) | CHUKNFATC1GSK3BDYRK1AMAP3K5 | |
| SCHEMBL16608595 | 0.87 | CHUK (0.38) | DGAT1CHUKDYRK1A | |
| SCHEMBL16608588 | 0.87 | DGAT1 (0.40) | DGAT1CHUKFEN1 | |
| SCHEMBL19626276 | 0.86 | PDE4B (0.42) | DGAT1NFATC1GSK3BDYRK1AMAP3K5 | |
| SCHEMBL16608644 | 0.86 | DGAT1 (0.41) | DGAT1CHUK | |
| SCHEMBL30692870 | 0.85 | DGAT1 (0.43) | DGAT1CHUKNFATC1GSK3BDYRK1A | |
| SCHEMBL21052340 | 0.85 | DGAT1 (0.43) | DGAT1CHUKNFATC1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981963-B2 | 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| EP-3049412-B1 | NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-12 | — | — | EP | disclosed |
| US-20160229851-A1 | NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2016-08-11 | — | — | US | disclosed |
| US-20160229851-A1 | NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2016-08-11 | — | — | US | disclosed |
| WO-2015044269-A1 | NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229851-A1 | NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K13 | DGAT1 2685/4885CHUK 30/4885NFATC1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.